The immunohistochemical expression of the oestrogen receptor (ER), HER-2/NEU and cytokeratin 8/18 and 5/6 in invasive breast carcinoma

Bharti Rattan, Mridu Manjari, S. K. Kahlon, Nikita Kalra, Amarpreet Bhalla, Surinder Paul

Research output: Contribution to journalArticle

Abstract

Introduction: Carcinoma is the most common malignancy of the breast and breast cancer is the most common non-skin malignancy in women. Ideally, prevention or very early detection of breast cancer reduce both morbidity and mortality of the disease. Effective use of tumour markers might permit the application of screening and treatment more efficiently. Materials and Methods: Immunohistochemical study was done in 39 cases of invasive breast carcinoma for further sub- classification for predicting prognosis and therapeutic approach. The cases were evaluated for expression of cytokeratin Ck 8/18, ER & Her-2/neu and 28 cases were subjected to cytokeratin Ck 5/6 including especially the cases negative for all the three markers. Results: ER was positive in seven cases with Her-2/neu being positive in eight cases and cytokeratin 8/18 positive in 33 cases. Cytokeratin 5/6 was positive in seven cases with four cases showing Ck 5/6 and Ck8/18 positivity, three cases showing positivity for Ck 5/6 only and three cases were negative for all the four markers. Conclusion: Thus classifying them to be luminal A, luminal B, combined, basal and null type respectively. Luminal A tmours show the best prognosis while luminal B tumours, combined, basal and null type are associated with less favouable outcome. Thus it is important to categorise them according to the cell of origin for prognosis and treatment.

Original languageEnglish (US)
Pages (from-to)1495-1498
Number of pages4
JournalJournal of Clinical and Diagnostic Research
Volume6
Issue number9
DOIs
StatePublished - Nov 15 2012
Externally publishedYes

Fingerprint

Keratin-5
Keratin-8
Keratin-18
Keratins
Estrogen Receptors
Breast Neoplasms
Tumor Biomarkers
Keratin-6
Tumors
Neoplasms
Screening
Early Detection of Cancer
Breast
Therapeutics
Morbidity
Carcinoma
Mortality

Keywords

  • Immunohistochemistry
  • Infiltrating ductal carcinoma
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

The immunohistochemical expression of the oestrogen receptor (ER), HER-2/NEU and cytokeratin 8/18 and 5/6 in invasive breast carcinoma. / Rattan, Bharti; Manjari, Mridu; Kahlon, S. K.; Kalra, Nikita; Bhalla, Amarpreet; Paul, Surinder.

In: Journal of Clinical and Diagnostic Research, Vol. 6, No. 9, 15.11.2012, p. 1495-1498.

Research output: Contribution to journalArticle

@article{af9f120fb44d46f8b7db5736c16969f8,
title = "The immunohistochemical expression of the oestrogen receptor (ER), HER-2/NEU and cytokeratin 8/18 and 5/6 in invasive breast carcinoma",
abstract = "Introduction: Carcinoma is the most common malignancy of the breast and breast cancer is the most common non-skin malignancy in women. Ideally, prevention or very early detection of breast cancer reduce both morbidity and mortality of the disease. Effective use of tumour markers might permit the application of screening and treatment more efficiently. Materials and Methods: Immunohistochemical study was done in 39 cases of invasive breast carcinoma for further sub- classification for predicting prognosis and therapeutic approach. The cases were evaluated for expression of cytokeratin Ck 8/18, ER & Her-2/neu and 28 cases were subjected to cytokeratin Ck 5/6 including especially the cases negative for all the three markers. Results: ER was positive in seven cases with Her-2/neu being positive in eight cases and cytokeratin 8/18 positive in 33 cases. Cytokeratin 5/6 was positive in seven cases with four cases showing Ck 5/6 and Ck8/18 positivity, three cases showing positivity for Ck 5/6 only and three cases were negative for all the four markers. Conclusion: Thus classifying them to be luminal A, luminal B, combined, basal and null type respectively. Luminal A tmours show the best prognosis while luminal B tumours, combined, basal and null type are associated with less favouable outcome. Thus it is important to categorise them according to the cell of origin for prognosis and treatment.",
keywords = "Immunohistochemistry, Infiltrating ductal carcinoma, Monoclonal antibodies",
author = "Bharti Rattan and Mridu Manjari and Kahlon, {S. K.} and Nikita Kalra and Amarpreet Bhalla and Surinder Paul",
year = "2012",
month = "11",
day = "15",
doi = "10.7860/JCDR/2012/4086.2542",
language = "English (US)",
volume = "6",
pages = "1495--1498",
journal = "Journal of Clinical and Diagnostic Research",
issn = "0973-709X",
publisher = "JCDR Research and Publications (Pvt) Limited",
number = "9",

}

TY - JOUR

T1 - The immunohistochemical expression of the oestrogen receptor (ER), HER-2/NEU and cytokeratin 8/18 and 5/6 in invasive breast carcinoma

AU - Rattan, Bharti

AU - Manjari, Mridu

AU - Kahlon, S. K.

AU - Kalra, Nikita

AU - Bhalla, Amarpreet

AU - Paul, Surinder

PY - 2012/11/15

Y1 - 2012/11/15

N2 - Introduction: Carcinoma is the most common malignancy of the breast and breast cancer is the most common non-skin malignancy in women. Ideally, prevention or very early detection of breast cancer reduce both morbidity and mortality of the disease. Effective use of tumour markers might permit the application of screening and treatment more efficiently. Materials and Methods: Immunohistochemical study was done in 39 cases of invasive breast carcinoma for further sub- classification for predicting prognosis and therapeutic approach. The cases were evaluated for expression of cytokeratin Ck 8/18, ER & Her-2/neu and 28 cases were subjected to cytokeratin Ck 5/6 including especially the cases negative for all the three markers. Results: ER was positive in seven cases with Her-2/neu being positive in eight cases and cytokeratin 8/18 positive in 33 cases. Cytokeratin 5/6 was positive in seven cases with four cases showing Ck 5/6 and Ck8/18 positivity, three cases showing positivity for Ck 5/6 only and three cases were negative for all the four markers. Conclusion: Thus classifying them to be luminal A, luminal B, combined, basal and null type respectively. Luminal A tmours show the best prognosis while luminal B tumours, combined, basal and null type are associated with less favouable outcome. Thus it is important to categorise them according to the cell of origin for prognosis and treatment.

AB - Introduction: Carcinoma is the most common malignancy of the breast and breast cancer is the most common non-skin malignancy in women. Ideally, prevention or very early detection of breast cancer reduce both morbidity and mortality of the disease. Effective use of tumour markers might permit the application of screening and treatment more efficiently. Materials and Methods: Immunohistochemical study was done in 39 cases of invasive breast carcinoma for further sub- classification for predicting prognosis and therapeutic approach. The cases were evaluated for expression of cytokeratin Ck 8/18, ER & Her-2/neu and 28 cases were subjected to cytokeratin Ck 5/6 including especially the cases negative for all the three markers. Results: ER was positive in seven cases with Her-2/neu being positive in eight cases and cytokeratin 8/18 positive in 33 cases. Cytokeratin 5/6 was positive in seven cases with four cases showing Ck 5/6 and Ck8/18 positivity, three cases showing positivity for Ck 5/6 only and three cases were negative for all the four markers. Conclusion: Thus classifying them to be luminal A, luminal B, combined, basal and null type respectively. Luminal A tmours show the best prognosis while luminal B tumours, combined, basal and null type are associated with less favouable outcome. Thus it is important to categorise them according to the cell of origin for prognosis and treatment.

KW - Immunohistochemistry

KW - Infiltrating ductal carcinoma

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84869999169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869999169&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2012/4086.2542

DO - 10.7860/JCDR/2012/4086.2542

M3 - Article

C2 - 23285439

AN - SCOPUS:84869999169

VL - 6

SP - 1495

EP - 1498

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 0973-709X

IS - 9

ER -